HeartSciences Stock Price, News & Analysis
Company Description
HeartSciences Inc. (HSCSW) – Company Overview
HeartSciences Inc. is described in its public disclosures as a healthcare information technology (HIT) and medical technology company focused on advancing electrocardiography (ECG or EKG) through the integration of artificial intelligence (AI). The company’s stated objective is to expand and improve the clinical utility of the ECG, with an emphasis on earlier detection of heart disease and improving frontline or point-of-care cardiac screening.
HeartSciences’ securities are registered on The Nasdaq Stock Market LLC, where its common stock trades under the symbol HSCS and its warrants trade under the symbol HSCSW, as noted in its SEC filings. The company is incorporated in Texas and identifies itself as an emerging growth company in its reports to the U.S. Securities and Exchange Commission (SEC).
Business Focus and Technology
According to multiple company news releases, HeartSciences is applying AI-based technology to ECGs to make this widely used test more informative for clinicians. Millions of ECGs are performed every week, and the company states that it aims to make ECGs a more valuable cardiac screening tool, particularly in frontline and point-of-care clinical settings. HeartSciences reports that it has built one of the largest libraries of AI-ECG algorithms and intends to provide these algorithms through a device-agnostic, cloud-based platform as well as a low-cost ECG hardware platform.
The company’s disclosures describe a focus on working with clinical experts so that its AI-ECG solutions fit into existing clinical care pathways. HeartSciences states that its technology is designed to integrate with hospital electronic health record (EHR) systems and existing workflows, with the goal of making it easier for clinicians to use AI-ECG tools to support patient care.
MyoVista Insights™ Platform
A central element of HeartSciences’ strategy is its MyoVista Insights software platform. In recent news and business updates, the company describes MyoVista Insights as a cloud-native, next-generation ECG management system. The platform is characterized as device-agnostic and vendor-agnostic, designed to work with existing ECG devices and multiple ECG file formats. HeartSciences states that MyoVista Insights is intended to modernize legacy ECG management systems, enhance clinical interpretation, improve workflow efficiency, streamline data management, and expand interoperability across a broad range of ECG devices.
The company further notes that MyoVista Insights is designed to function as a marketplace for AI-ECG algorithms. In its public communications, HeartSciences explains that the platform is intended to host both its own AI-ECG algorithms and third-party, FDA-cleared algorithms. The company highlights that MyoVista Insights is classified as a Medical Device Data System (MDDS), which it states carries lower regulatory requirements and is exempt from 510(k) clearance. HeartSciences indicates that this classification is expected to reduce organizational costs and accelerate commercial rollout compared with regulated medical devices.
HeartSciences reports that MyoVista Insights has undergone a phased rollout, beginning with early adopter reference sites. The company has announced the signing of its first commercial customer for the platform, Westcliffe Health Innovations in the United Kingdom, which provides cardiology services to the U.K. National Health Service (NHS). HeartSciences describes this implementation as a key reference deployment for the U.K. market.
MyoVista® wavECG™ Device
In addition to its software platform, HeartSciences is developing the MyoVista wavECG device. Company news releases describe MyoVista wavECG as a resting 12-lead ECG device designed to provide conventional ECG information while also supporting AI-enabled diagnostic solutions. HeartSciences states that the device is designed to host AI-ECG algorithms and to provide diagnostic information related to cardiac dysfunction that has traditionally required cardiac imaging.
The company has disclosed that it has submitted the MyoVista wavECG device to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance. HeartSciences reports that it elected to separate the FDA submissions for the device and for an impaired cardiac relaxation AI-ECG software algorithm, following updated guidelines from the American Society of Echocardiography (ASE) for assessing Left Ventricular Diastolic Dysfunction (LVDD). The company indicates that this approach is intended to streamline regulatory review of the device while allowing additional development and validation of the algorithm to align with new clinical standards.
AI-ECG Algorithms and Clinical Applications
HeartSciences highlights its AI-ECG algorithm library as a core asset. The company reports that its first product candidate for FDA clearance, the MyoVista wavECG, is designed to provide diagnostic information related to cardiac dysfunction in addition to conventional ECG data. It also discloses work on specific AI-ECG algorithms, including an algorithm for detecting aortic stenosis, for which the company has received FDA Breakthrough Device designation, and a planned cloud-based algorithm for detecting reduced ejection fraction targeted for future FDA submission.
In its public statements, HeartSciences notes that its aortic stenosis ECG algorithm is intended to detect moderate-to-severe aortic stenosis using AI applied to ECG data. The company reports that, once cleared, this algorithm is expected to be accessible through the MyoVista Insights cloud-based platform with integration into hospital EHR systems and without the need for additional hardware or testing. HeartSciences also describes the use of deep learning techniques and large ECG datasets in the development of this algorithm.
Regulatory and Reimbursement Environment
The company’s news releases reference several regulatory and reimbursement developments relevant to its business. HeartSciences notes that the Centers for Medicare & Medicaid Services (CMS) has approved reimbursement codes for AI-ECG algorithms, with reimbursement described as additive to conventional ECG test reimbursement. The company states that this framework is expected, in its view, to support adoption of AI-ECG by benefiting hospitals and institutions, insurers, physicians, and patients.
HeartSciences also reports that it has received FDA Breakthrough Device designation for its aortic stenosis ECG algorithm, which it presents as an important milestone for its AI-ECG strategy. In addition, the company discloses that MyoVista Insights is classified as an MDDS, which it associates with lower regulatory requirements compared with regulated medical devices.
Intellectual Property and Patents
HeartSciences emphasizes its intellectual property portfolio in multiple announcements. The company reports that it has been granted a foundational U.S. patent covering the estimation of echocardiographic parameters indicative of heart function using an ECG. It further states that, in total, it has been granted 10 U.S. patents and 34 international patents, for a total of 44 granted patents worldwide. The company notes that its international patents cover key countries, including China, Brazil, Canada, India, South Korea, Mexico, and several European markets such as Germany, France, the United Kingdom, Italy, and the Netherlands.
In its commentary, HeartSciences describes this patent portfolio as reinforcing the value of its AI-ECG intellectual property and supporting its position in the AI-ECG field.
Capital Markets, Warrants, and Nasdaq Listing
HeartSciences’ SEC filings identify the company as a Texas corporation with its common stock and warrants listed on The Nasdaq Stock Market LLC under the symbols HSCS and HSCSW, respectively. The filings show that the company has used various capital-raising mechanisms, including an at-the-market offering program under an Equity Distribution Agreement with Maxim Group LLC and a Regulation A (Reg A) offering of units consisting of Series D preferred stock and warrants.
In an 8-K filing, HeartSciences reports that it amended its Equity Distribution Agreement to increase the maximum amount of common stock that may be offered and sold under that program. Other 8-K filings describe progress in the Reg A offering, including gross proceeds received, issuance of units, conversion of Series D preferred stock into common stock, and exchanges of debt into equity.
Another 8-K filing notes that on September 16, 2025, Nasdaq’s Listing Qualifications Department informed the company that it had regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders’ equity for continued listing on The Nasdaq Capital Market.
Corporate Governance and Bylaws
HeartSciences has also reported changes to its corporate governance documents. In an 8-K filing, the company discloses that its Board of Directors adopted amendments to its bylaws to address matters such as a jury trial waiver for certain internal entity claims, an ownership threshold for shareholders to institute or maintain derivative proceedings, and clarifications to an exclusive forum provision. These amendments were adopted in light of changes to the Texas Business Organizations Code and became effective on June 27, 2025.
Company Status
Based on the provided SEC filings and news releases, HeartSciences continues to file periodic and current reports with the SEC and remains listed on The Nasdaq Stock Market LLC for both its common stock (HSCS) and warrants (HSCSW). The available documents do not indicate a completed merger, acquisition, bankruptcy filing, or delisting of the company’s securities.
FAQs about HeartSciences Inc. (HSCSW)
- What does HeartSciences Inc. do?
HeartSciences describes itself as a healthcare information technology and medical technology company focused on applying AI-based technology to ECGs/EKGs. Its goal is to expand and improve the clinical utility of ECGs, particularly for earlier detection of heart disease and frontline cardiac screening. - How is HeartSciences using artificial intelligence in cardiology?
According to company disclosures, HeartSciences has developed one of the largest libraries of AI-ECG algorithms. These algorithms are intended to run on its MyoVista Insights cloud-based platform and on its MyoVista wavECG hardware, with applications that include detecting cardiac dysfunction and specific conditions such as aortic stenosis. - What is the MyoVista Insights platform?
MyoVista Insights is described as a cloud-native, device-agnostic ECG management system. HeartSciences states that it is designed to modernize legacy ECG management, host AI-ECG algorithms from the company and third parties, integrate with hospital EHR systems, and improve workflow efficiency and data management. - What is the MyoVista wavECG device?
The company’s MyoVista wavECG device is described as a resting 12-lead ECG that provides conventional ECG information and is designed to deliver additional diagnostic information related to cardiac dysfunction. HeartSciences reports that the device is designed to host AI-ECG algorithms and that it has submitted the device to the FDA for 510(k) premarket clearance. - What regulatory milestones has HeartSciences reported?
HeartSciences has disclosed that it submitted the MyoVista wavECG device to the FDA for 510(k) clearance and that it received FDA Breakthrough Device designation for its aortic stenosis ECG algorithm. The company also notes that MyoVista Insights is classified as a Medical Device Data System, which it associates with lower regulatory requirements. - How does HeartSciences describe its reimbursement environment?
In its news releases, HeartSciences states that CPT reimbursement codes for AI-ECG have been approved by CMS and that these codes are additive to conventional ECG reimbursement. The company indicates that this reimbursement framework is expected to support adoption of AI-ECG algorithms provided through its platform. - What intellectual property does HeartSciences report owning?
HeartSciences reports that it has been granted 10 U.S. patents and 34 international patents, for a total of 44 granted patents. The company highlights a foundational U.S. patent covering estimation of echocardiographic parameters using ECG and notes that its international patents span several countries and European markets. - Where are HeartSciences’ securities listed?
According to its SEC filings, HeartSciences’ common stock is listed on The Nasdaq Stock Market LLC under the symbol HSCS, and its warrants are listed on Nasdaq under the symbol HSCSW. - Has HeartSciences faced any Nasdaq listing issues?
The company has disclosed that it previously received a notice from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement. In a later 8-K, HeartSciences reports that Nasdaq notified the company that it had regained compliance with this requirement and that the matter was closed. - How is HeartSciences raising capital?
HeartSciences’ SEC filings describe an at-the-market offering program under an Equity Distribution Agreement with Maxim Group LLC and a Regulation A offering of units consisting of Series D preferred stock and warrants. The company has reported proceeds from these offerings and exchanges of debt into equity.